Diana Ernst, RPh

Editorial Director https://www.neurologyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Epilepsy

FDA Approves Nayzilam Nasal Spray to Treat Seizure Clusters

Diana Ernst, RPh

May 23, 2019

The Food and Drug Administration (FDA) has approved Nayzilam (midazolam) nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.

General Neurology

Xeomin Approved as First-Line Treatment for Blepharospasm

Diana Ernst, RPh

May 21, 2019

The FDA has approved Xeomin (incobotulinumtoxinA; Merz) as a first-line treatment for blepharospasm in adults.

Neuromuscular Disorders

Ruzurgi Approved for Pediatric Patients With Lambert-Eaton Myasthenic Syndrome

Diana Ernst, RPh

May 8, 2019

The Food and Drug Administration (FDA) has approved Ruzurgi (amifampridine; Jacobus Pharmaceutical) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to <17 years of age.

AAN 2019 Conference

Suvorexant Evaluated for Insomnia in Patients With Alzheimer Disease Dementia

Diana Ernst, RPh

May 7, 2019

A study evaluating the safety and efficacy of suvorexant for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia was presented at AAN 2019.

Sleep Disorders

FDA: Boxed Warning, Contraindication Added to Several Insomnia Medications

Diana Ernst, RPh

May 2, 2019

A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.

Migraine and Headache

Fremanezumab Cluster Headache Development Program Discontinued

Diana Ernst, RPh

April 25, 2019

Teva announced that the ENFORCE phase 3 program for fremanezumab in the treatment of cluster headaches will be discontinued following results from a futility analysis.

Uncategorized

Eptinezumab Biologics License Application Accepted by the FDA for Review

Diana Ernst, RPh

April 23, 2019

The FDA has accepted for review the Biologics License Application for eptinezumab (Alder BioPharmaceuticals), an investigational CGRP inhibitor for migraine prevention.

Pediatric Neurology

FDA Allows Marketing of First Medical Device for Treatment of ADHD

Diana Ernst, RPh

April 23, 2019

The FDA has permitted for marketing the first medical device indicated for the treatment of attention deficit hyperactivity disorder ADHD.

General Neurology

New Tool Alerts Public to Unlawfully Marketed Dietary Supplement Ingredients

Diana Ernst, RPh

April 18, 2019

In an effort to better alert the public of unlawful ingredients in dietary supplements, the FDA has created the Dietary Supplement Ingredient Advisory List, a new reference tool for consumers and manufacturers.

Multiple Sclerosis

Short-Course Oral Treatment Option Approved for Relapsing Forms of MS

Diana Ernst, RPh

April 1, 2019

EMD Serono announced that the Food and Drug Administration (FDA) has approved Mavenclad (cladribine) tablets for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS).

Next post in Multiple Sclerosis